ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Kansas' MULTIDISCIPLINARY CANCER CARE TEAMs and the PATIENTS THEY SERVE since 1994
Meetings & Education
Financial Advocacy & Patient Assistance
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
Patient Advocacy Organizations
National Professional Organizations
KaSCO Corporate Members
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
With Project Orbis Collaboration, FDA Approves New Treatment for Endometrial Cancer
On September 17, the U.S. Food and Drug Administration (FDA) announced
, an initiative of the FDA Oncology Center of Excellence (OCE). Project Orbis provides a framework for concurrent submission and review of oncology drugs among its international partners.
As part of Project Orbis, in conjunction with decisions by the Australian Therapeutic Goods Administration (TGA) and Health Canada, the
FDA today granted accelerated approval to Lenvima (lenvatinib) in combination with Keytruda (pembrolizumab)
for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation. Collaboration among international regulators through Project Orbis allowed for simultaneous decisions in all three countries.
Read FDA announcement on Project Orbis
Read more on
FDA approval of lenvatinib in combination with pembrolizumab for certain patients with advanced endometrial carcinoma